2018
Disparities by race, age, and sex in the improvement of survival for lymphoma: Findings from a population-based study
Mukhtar F, Boffetta P, Dabo B, Park JY, Tran CTD, Tran TV, Tran HT, Whitney M, Risch HA, Le LC, Zheng W, Shu XO, Luu HN. Disparities by race, age, and sex in the improvement of survival for lymphoma: Findings from a population-based study. PLOS ONE 2018, 13: e0199745. PMID: 29995909, PMCID: PMC6040734, DOI: 10.1371/journal.pone.0199745.Peer-Reviewed Original ResearchConceptsLymphoma patientsHodgkin's lymphomaAge groupsHazard ratioDisease-specific mortalityFive-year survivalHodgkin's lymphoma patientsImprovement of survivalPopulation-based studyProportional hazards regressionConfidence intervalsCause-specific mortalityIncident lymphoma casesSEER cancer registryYears of ageOlder age groupsPatients 20Surveillance EpidemiologyCancer RegistrySurvival improvementHazards regressionLymphoma casesNHL survivalPatientsLymphoma
2017
Aspirin Use and Reduced Risk of Pancreatic Cancer
Risch HA, Lu L, Streicher SA, Wang J, Zhang W, Ni Q, Kidd MS, Yu H, Gao YT. Aspirin Use and Reduced Risk of Pancreatic Cancer. Cancer Epidemiology Biomarkers & Prevention 2017, 26: 68-74. PMID: 27999143, PMCID: PMC5225096, DOI: 10.1158/1055-9965.epi-16-0508.Peer-Reviewed Original ResearchConceptsPancreatic cancerAspirin useRegular useConfidence intervalsLong-term aspirin useControl subjects frequencyLow-dose aspirinAvoidance of smokingBody mass indexPopulation-based studyUnconditional logistic regressionABO blood groupRisk-benefit analysisAspirin typeCagA seropositivityDiabetes mellitusMass indexCigarette smokingCardiovascular diseaseAspirinCancerCertain cancersLogistic regressionBlood groupSubjects frequency
2015
Dietary intake of flavonoids and oesophageal and gastric cancer: incidence and survival in the United States of America (USA)
Petrick JL, Steck SE, Bradshaw PT, Trivers KF, Abrahamson PE, Engel LS, He K, Chow WH, Mayne ST, Risch HA, Vaughan TL, Gammon MD. Dietary intake of flavonoids and oesophageal and gastric cancer: incidence and survival in the United States of America (USA). British Journal Of Cancer 2015, 112: 1291-1300. PMID: 25668011, PMCID: PMC4385952, DOI: 10.1038/bjc.2015.25.Peer-Reviewed Original ResearchConceptsOdds ratioHazard ratioFlavonoid intakeGastric cancerFood frequency questionnaire responsesMulticentre population-based studyIntake of anthocyanidinsLowest intake quartilesTotal flavonoid intakeFrequency-matched controlsPopulation-based studyProportional hazards regressionRisk of mortalityUSDA flavonoid databasesCase participantsAnthocyanidin intakeIntake quartilesHazards regressionVital statusDietary intakeChemopreventive effectsEpidemiologic studiesTumor typesFlavonoid databaseCancerSurvival in women with ovarian cancer with and without microsatellite instability.
Segev Y, Zhang S, Akbari MR, Sun P, Sellers TA, McLaughlin J, Risch HA, Rosen B, Shaw P, Schildkraut J, Narod SA, Pal T. Survival in women with ovarian cancer with and without microsatellite instability. European Journal Of Gynaecological Oncology 2015, 36: 681-4. PMID: 26775351.Peer-Reviewed Original ResearchConceptsPresence of MSIEpithelial ovarian cancerOvarian cancerMicrosatellite instabilityPrognostic factorsMSI statusNational Cancer Institute criteriaSpecific prognostic factorsPopulation-based studyOvarian cancer patientsHazard ratioPathologic featuresCancer patientsSubgroup analysisDefective mismatch repairSurvival differencesMulti-variate analysisCancerTumor samplesMSI markersSignificant differencesPatientsSurvivalWomenMismatch repair
2014
Telomere Length and Mortality Following a Diagnosis of Ovarian Cancer
Kotsopoulos J, Prescott J, De Vivo I, Fan I, Mclaughlin J, Rosen B, Risch H, Sun P, Narod SA. Telomere Length and Mortality Following a Diagnosis of Ovarian Cancer. Cancer Epidemiology Biomarkers & Prevention 2014, 23: 2603-2606. PMID: 25159293, PMCID: PMC4221534, DOI: 10.1158/1055-9965.epi-14-0885.Peer-Reviewed Original ResearchConceptsLength z-scoreOvarian cancerZ-scoreTelomere lengthOvarian cancer-specific mortalityLarge population-based studyCancer-specific mortalityIncident ovarian cancerPopulation-based studyConfidence intervalsProportional hazards modelComputerized record linkagePeripheral blood leukocytesRelative telomere lengthNonserous tumorsChart reviewPrognostic roleVital statusPrognostic significanceLowest quartileBlood leukocytesHazards modelCancerCancer developmentQuartileRisk Factors for Ovarian Cancers With and Without Microsatellite Instability
Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Sun P, Narod SA, Schildkraut J. Risk Factors for Ovarian Cancers With and Without Microsatellite Instability. International Journal Of Gynecological Cancer 2014, 24: 664-669. PMID: 24755492, DOI: 10.1097/igc.0000000000000134.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdenocarcinoma, MucinousBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsCanadaCystadenocarcinoma, SerousDNA, NeoplasmEndometrial NeoplasmsFemaleGenetic Predisposition to DiseaseHumansMicrosatellite InstabilityMicrosatellite RepeatsMiddle AgedMutationNeoplasm StagingOvarian NeoplasmsPrognosisRisk FactorsSyndromeUnited StatesConceptsOvarian cancer patientsOral contraceptive useBody mass indexEpithelial ovarian cancerOvarian cancerCancer patientsHistologic subtypeMass indexTubal ligationRisk factorsBRCA2 mutationsContraceptive usePast oral contraceptive usePrimary epithelial ovarian cancerOvarian cancer risk factorsBRCA1 mutationsNational Cancer Institute criteriaProtective factorsSpecific histologic subtypesCancer risk factorsPopulation-based studyMSI-high cancersCases of cancerMSI-high tumorsBRCA2 mutation status
2013
Preventing ovarian cancer through genetic testing: a population‐based study
Finch A, Bacopulos S, Rosen B, Fan I, Bradley L, Risch H, McLaughlin JR, Lerner‐Ellis J, Narod SA. Preventing ovarian cancer through genetic testing: a population‐based study. Clinical Genetics 2013, 86: 496-499. PMID: 24199689, DOI: 10.1111/cge.12313.Peer-Reviewed Original ResearchConceptsOvarian cancerGenetic testingGenetic testing criteriaInvasive ovarian cancerPopulation-based studyOvarian cancer patientsBRCA2 gene mutationsGenetic test resultsDevelopment of cancerCancer patientsBRCA2 mutationsMutation carriersUnselected casesEligibility criteriaCancerPatientsGene mutationsProvince of OntarioWomenPotential utilityPopulation levelBRCA1MutationsRisk Factors for Ovarian Cancers With and Without Microsatellite Instability
Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Ping S, Narod SA, Schildkraut J. Risk Factors for Ovarian Cancers With and Without Microsatellite Instability. International Journal Of Gynecological Cancer 2013, 23: 1010. PMID: 23748177, PMCID: PMC3740723, DOI: 10.1097/igc.0b013e31829a5527.Peer-Reviewed Original ResearchConceptsOvarian cancer patientsOral contraceptive useBody mass indexEpithelial ovarian cancerOvarian cancerCancer patientsHistologic subtypeMass indexHistologic findingsTubal ligationRisk factorsContraceptive usePast oral contraceptive usePrimary epithelial ovarian cancerOvarian cancer risk factorsBRCA1 mutationsNational Cancer Institute criteriaProtective factorsDifferent histologic findingsSpecific histologic subtypesCancer risk factorsPopulation-based studyMSI-high cancersMSI-high tumorsBRCA2 mutation status
2012
Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer
Pal T, Akbari MR, Sun P, Lee JH, Fulp J, Thompson Z, Coppola D, Nicosia S, Sellers TA, McLaughlin J, Risch HA, Rosen B, Shaw P, Schildkraut J, Narod SA. Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer. British Journal Of Cancer 2012, 107: 1783-1790. PMID: 23047549, PMCID: PMC3493867, DOI: 10.1038/bjc.2012.452.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingCarcinoma, Ovarian EpithelialColorectal NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisDNA Mismatch RepairDNA-Binding ProteinsFemaleHumansMiddle AgedMutationMutL Protein Homolog 1MutS Homolog 2 ProteinNeoplasms, Glandular and EpithelialNuclear ProteinsOvarian NeoplasmsConceptsHereditary non-polyposis colorectal cancerPopulation-based studyEpithelial ovarian cancerOvarian cancerNon-polyposis colorectal cancerNon-serous histologyPathogenic mutation carriersMismatch repair gene mutationsGene mutationsOvarian cancer patientsHNPCC genesPopulation-based sampleRepair gene mutationsMismatch repair genesFamily history informationPathogenic missense variantsColorectal cancerMean ageCancer patientsMSH6 mutationsTreatment decisionsMutation carriersFrequency of mutationsPathogenic variantsCancerHeight, weight, BMI and ovarian cancer survival
Kotsopoulos J, Moody JR, Fan I, Rosen B, Risch HA, McLaughlin JR, Sun P, Narod SA. Height, weight, BMI and ovarian cancer survival. Gynecologic Oncology 2012, 127: 83-87. PMID: 22713293, DOI: 10.1016/j.ygyno.2012.05.038.Peer-Reviewed Original ResearchConceptsBody mass indexOvarian cancer survivalOvarian cancer-specific mortalityCancer-specific mortalityHazard ratioCancer survivalOvarian cancerLarge population-based studyBMI 5 yearsFatal gynecologic malignancyPopulation-based studyEpithelial ovarian cancerConfidence intervalsOvarian cancer prognosisProportional hazards modelChart reviewGynecologic malignanciesClinicopathologic featuresHistologic subtypeMass indexVital statusModifiable factorsRisk factorsHazards modelCancer prognosis
2011
Nonsteroidal Anti-inflammatory Drug Use Reduces Risk of Adenocarcinomas of the Esophagus and Esophagogastric Junction in a Pooled Analysis
Liao LM, Vaughan TL, Corley DA, Cook MB, Casson AG, Kamangar F, Abnet CC, Risch HA, Giffen C, Freedman ND, Chow W, Sadeghi S, Pandeya N, Whiteman DC, Murray LJ, Bernstein L, Gammon MD, Wu AH. Nonsteroidal Anti-inflammatory Drug Use Reduces Risk of Adenocarcinomas of the Esophagus and Esophagogastric Junction in a Pooled Analysis. Gastroenterology 2011, 142: 442-452.e5. PMID: 22108196, PMCID: PMC3488768, DOI: 10.1053/j.gastro.2011.11.019.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdolescentAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalAnticarcinogenic AgentsAustraliaCanadaCase-Control StudiesCohort StudiesEsophageal NeoplasmsEsophagogastric JunctionFemaleHumansLogistic ModelsMaleMiddle AgedOdds RatioRisk AssessmentRisk FactorsStomach NeoplasmsTime FactorsUnited StatesYoung AdultConceptsNonsteroidal anti-inflammatory drugsEsophagogastric junctional adenocarcinomaRisk of EACNSAID useEsophageal adenocarcinomaPooled analysisOdds ratioEsophagogastric junctionNonaspirin nonsteroidal anti-inflammatory drugsStudy-specific odds ratiosRandom-effects meta-analysis modelEffects meta-analysis modelPrevention of adenocarcinomaUse of aspirinSignificant reduced riskPopulation-based studyConfidence intervalsAnti-inflammatory drugsDuration of useEsophageal Adenocarcinoma ConsortiumMeta-analysis modelLogistic regression modelsJunctional adenocarcinomaMedication typeEAC riskGenetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer
Zeng H, Yu H, Lu L, Jain D, Kidd MS, Saif MW, Chanock SJ, Hartge P, Risch H. Genetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer. Pancreas 2011, 40: 657-663. PMID: 21487324, PMCID: PMC3116071, DOI: 10.1097/mpa.0b013e31821268d1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overATP Binding Cassette Transporter, Subfamily G, Member 2ATP-Binding Cassette TransportersCase-Control StudiesConnecticutDihydrouracil Dehydrogenase (NADP)FemaleGenetic MarkersGenetic VariationGenome-Wide Association StudyHumansMaleMiddle AgedNeoplasm ProteinsPancreatic NeoplasmsPolymorphism, Single NucleotidePrognosisProportional Hazards ModelsSerpinsSurvival AnalysisTreatment OutcomeConceptsPancreatic cancerOverall survivalCancer survivalProportional hazards regression modelsSurvival of patientsPopulation-based studyPancreatic cancer survivalHazards regression modelsGerm-line genetic variationEvidence of associationClinical outcomesCancer patientsTreatment outcomesTreatment responseSignificant associationPatientsCancerPrevious genome-wide association study dataRadiotherapyPutative markerGenetic polymorphismsSurvivalDPYD geneChemotherapyEvidence of interaction
2010
Genetic Variation in the Prostate Stem Cell Antigen Gene and Upper Gastrointestinal Cancer in White Individuals
Lochhead P, Frank B, Hold GL, Rabkin CS, Ng MT, Vaughan TL, Risch HA, Gammon MD, Lissowska J, Weck MN, Raum E, Müller H, Illig T, Klopp N, Dawson A, McColl KE, Brenner H, Chow W, El–Omar E. Genetic Variation in the Prostate Stem Cell Antigen Gene and Upper Gastrointestinal Cancer in White Individuals. Gastroenterology 2010, 140: 435-441. PMID: 21070776, PMCID: PMC3031760, DOI: 10.1053/j.gastro.2010.11.001.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAntigens, NeoplasmCarcinoma, Squamous CellCase-Control StudiesEsophageal NeoplasmsFemaleGastritis, AtrophicGastrointestinal NeoplasmsGenetic Predisposition to DiseaseGPI-Linked ProteinsHelicobacter InfectionsHelicobacter pyloriHumansMaleNeoplasm ProteinsPolymorphism, Single NucleotideRiskWhite PeopleConceptsChronic atrophic gastritisNoncardia gastric cancerUpper gastrointestinal cancerGastric cancer casesProstate stem cell antigen (PSCA) geneCancer casesGastric cancerAtrophic gastritisGastrointestinal cancerRs2294008 polymorphismWhite individualsRisk allelesHelicobacter pylori-infected subjectsPylori-infected subjectsPopulation-based studySquamous cell carcinomaGastric cancer patientsGastric cardia cancerCase-control studyEsophageal cancer casesDiffuse histologic typeAntigen geneProximal cancersGastric atrophyHistologic type
2008
Uptake of clinical genetic testing for ovarian cancer in Ontario: A population-based study
Metcalfe KA, Fan I, McLaughlin J, Risch HA, Rosen B, Murphy J, Bradley L, Armel S, Sun P, Narod SA. Uptake of clinical genetic testing for ovarian cancer in Ontario: A population-based study. Gynecologic Oncology 2008, 112: 68-72. PMID: 19019415, PMCID: PMC3074978, DOI: 10.1016/j.ygyno.2008.10.007.Peer-Reviewed Original ResearchConceptsInvasive ovarian cancerClinical genetic testingOvarian cancerGenetic testingGenetic test resultsBlood samplesPositive genetic test resultOntario Cancer RegistryPopulation-based studyEpithelial ovarian cancerProportion of womenCancer RegistryRisk factorsBRCA2 mutationsClinical testingCancerWomenBRCA2BRCA1Small proportionPrevious testingMutationsPatientsTestingRegistry
2007
Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study
McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL, Offit K, Kauff N, Domchek S, Tung N, Friedman E, Foulkes W, Sun P, Narod SA, Group O. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. The Lancet Oncology 2007, 8: 26-34. PMID: 17196508, DOI: 10.1016/s1470-2045(06)70983-4.Peer-Reviewed Original ResearchConceptsInvasive ovarian cancerCarriers of BRCA1Case-control studyOral contraceptivesOvarian cancerBRCA2 mutationsTubal ligationRisk factorsBRCA1 mutationsReproductive risk factorsPopulation-based studyOvarian cancer riskPossible adverse effectsYear of birthInternational registryMenstrual cycleOdds ratioBreast cancerMutation carriersReproductive historyContraceptivesBRCA2 genesCancerAdverse effectsWomen
2006
PGR +331 A/G and Increased Risk of Epithelial Ovarian Cancer
Risch HA, Bale AE, Beck PA, Zheng W. PGR +331 A/G and Increased Risk of Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers & Prevention 2006, 15: 1738-1741. PMID: 16985038, DOI: 10.1158/1055-9965.epi-06-0272.Peer-Reviewed Original ResearchConceptsOvarian cancerA allelePostmenopausal womenProgesterone receptor gene polymorphismHistologic tumor typePopulation-based studyEpithelial ovarian cancerEffect of progesteroneReceptor gene polymorphismsPremenopausal womenEndometrial cancerMenopausal statusOral contraceptivesOvarian neoplasiaProgesterone receptorProgestin exposureG genotypeGG genotypeGene polymorphismsTumor typesReceptor isoformsCancerWomenRiskProgesterone